CTSB and neoplasm: Furthermore, because CtsB is known both to participate in tumor progression by promoting the migration and invasion of tumor cells[6d, 13] and to induce adaptive response to chemotherapy,[6c] the LNC-NS-629 system may combine the efficient targeted delivery of drugs and diagnostic agents with a sustained inhibition of CtsB by NS-629, thereby providing an additional benefit for treatment.